Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Non-Small-Cell Lung Cancer (NSCLC)

TAGRISSO Plus Chemotherapy Shows Great Results In Clinical Trial For NSCLC

Posted on May 22, 2023
Post Views: 281

Non-Small-Cell Lung Cancer (NSCLC)Tagrisso alone did not produce as much good result then TAGRISSO (osimertinib) plus chemotherapy did for patients with stage locally advanced or metastatic non-small cell lung cancer (NSCLC) advanced EGFR mutations in phase 3 FLAURA2 trial at AstraZeneca.

According to AstraZeneca press release “the findings of the FLAURA2 trial showed that adding Tagrisso to chemotherapy significantly improved progression-free survival, or the length of time a cancer patient lives with disease without worsening, rather than chemotherapy alone.”

“As the global standard of care for EGFR-mutated non-small cell lung cancer, osimertinib monotherapy has transformed the treatment landscape allowing many patients the opportunity to achieve improved survival. FLAURA2 provides compelling evidence that the addition of chemotherapy to osimertinib can provide a new option for patients and clinicians that further improves outcomes compared to osimertinib alone and as such, can further delay treatment resistance and disease progression.” said by Pasi A. Jänne, MD, PhD, medical oncologist at Dana-Farber Cancer Institute and principal investigator for the FLAURA2 trial.

Susan Galbraith – Executive Vice President and Oncology R&D at AstraZeneca said “These significant FLAURA2 results show TAGRISSO has the potential to offer patients in the first-line setting a new treatment option that can extend the time they live without their disease progressing. This meaningfully builds on successive trials which have demonstrated improved clinical benefit with TAGRISSO in patients with EGFR-mutated lung cancer.”

Several factors including overall survival, progression-free survival, objective response rate and duration of response, among others were monitored throughout the trial. According to the press release the data will we presented at a forthcoming medical meeting and shared with global health authorities.

Each year 30–40% of patients in Asia are diagnosed with EGFRm NSCLC while in the US and Europe 80–85% of patients are diagnosed with NSCLC and approximately 70% are diagnosed with advanced NSCLC. Since NSCLC is the most common form of lung cancer, more research and better results are milestones for effective treatment.

The information shared in this blog is for educational purposes only and is certainly not a substitute for medical advice. Please consult your healthcare practitioner for any medical needs.

Subscribe to our newsletter or follow us on Facebook or Twitter today and never miss out an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,324)
  • Lung Cancer: Symptoms and Treatment (5,655)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d